Comparative evaluation of microplate enzyme-linked immunosorbent assay versus plaque reduction assay for antiviral susceptibility testing of herpes simplex virus isolates.
作者信息
Safrin S, Palacios E, Leahy B J
机构信息
Herpes Virus Research Laboratory, San Francisco General Hospital, CA 94110, USA.
出版信息
Antimicrob Agents Chemother. 1996 Apr;40(4):1017-9. doi: 10.1128/AAC.40.4.1017.
Abstract
We tested the antiviral susceptibilities of 30 clinical isolates of herpes simplex virus using the microplate in situ enzyme-linked immunosorbent assay (MISE) and the plaque reduction assay (PRA). There was concordance for 26 of 30 acyclovir results and all 30 foscarnet results. MISE and PRA results each predicted the response to acyclovir in 12 of 14 instances and the response to foscarnet in 8 instances. MISE is more rapid than PRA, has an objective endpoint, and correlates well with the clinical response to therapy.
摘要
相似文献
1
Comparative evaluation of microplate enzyme-linked immunosorbent assay versus plaque reduction assay for antiviral susceptibility testing of herpes simplex virus isolates.
Antimicrob Agents Chemother. 1996 Apr;40(4):1017-9. doi: 10.1128/AAC.40.4.1017.
2
Cytopathic effect inhibition assay for determining the in-vitro susceptibility of herpes simplex virus to antiviral agents.
J Antimicrob Chemother. 1999 Nov;44(5):705-8. doi: 10.1093/jac/44.5.705.
3
A blinded comparison of two methods of viral susceptibility testing: plaque reduction assay versus microplate in situ ELISA.
J Virol Methods. 1996 Jan;56(1):85-90. doi: 10.1016/0166-0934(95)01957-x.
4
A rapid screen test for in vitro susceptibility of clinical herpes simplex virus isolates.
J Infect Dis. 1994 Apr;169(4):879-82. doi: 10.1093/infdis/169.4.879.
5
Standardisation of a microplate in situ ELISA (MISE-test) for the susceptibility testing of herpes simplex virus to acyclovir.
J Virol Methods. 1994 Jun;48(1):93-108. doi: 10.1016/0166-0934(94)90092-2.
6
Correlation between response to acyclovir and foscarnet therapy and in vitro susceptibility result for isolates of herpes simplex virus from human immunodeficiency virus-infected patients.
Antimicrob Agents Chemother. 1994 Jun;38(6):1246-50. doi: 10.1128/AAC.38.6.1246.
7
Simultaneous titration and phenotypic antiviral drug susceptibility testing for herpes simplex virus 1 and 2.
J Clin Virol. 2014 Nov;61(3):382-6. doi: 10.1016/j.jcv.2014.08.015. Epub 2014 Aug 28.
8
In vitro activity of penciclovir against clinical isolates of acyclovir-resistant and foscarnet-resistant herpes simplex virus.
Antimicrob Agents Chemother. 1993 Oct;37(10):2241-3. doi: 10.1128/AAC.37.10.2241.
9
[In vitro susceptibility study of herpes simplex virus to acyclovir and foscarnet. Are routine susceptibility studies necessary?].
Enferm Infecc Microbiol Clin. 2002 Jan;20(1):25-7. doi: 10.1016/s0213-005x(02)72727-4.
10
Characterization of the DNA polymerase and thymidine kinase genesof herpes simplex virus isolates from AIDS patients in whom acyclovirand foscarnet therapy sequentially failed.
J Infect Dis. 1999 Aug;180(2):487-90. doi: 10.1086/314900.
引用本文的文献
1
Practical updates in clinical antiviral resistance testing.
J Clin Microbiol. 2024 Aug 14;62(8):e0072823. doi: 10.1128/jcm.00728-23. Epub 2024 Jul 25.
2
Laboratory diagnosis of viral infection.
Handb Clin Neurol. 2014;123:123-47. doi: 10.1016/B978-0-444-53488-0.00005-5.
3
Herpes simplex virus: isolation, cytopathological characterization and antiviral sensitivity.
An Bras Dermatol. 2014 May-Jun;89(3):448-52. doi: 10.1590/abd1806-4841.20142574.
4
Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management.
Antimicrob Agents Chemother. 2011 Feb;55(2):459-72. doi: 10.1128/AAC.00615-10. Epub 2010 Nov 15.
5
Application of real-time PCR for determination of antiviral drug susceptibility of herpes simplex virus.
Antimicrob Agents Chemother. 2002 Sep;46(9):2943-7. doi: 10.1128/AAC.46.9.2943-2947.2002.
本文引用的文献
1
A comparative evaluation of three methods of antiviral susceptibility testing of clinical herpes simplex virus isolates.
Clin Diagn Virol. 1995 Jul;4(1):81-91. doi: 10.1016/0928-0197(94)00059-4.
2
Foscarnet-resistant herpes simplex virus infection in patients with AIDS.
J Infect Dis. 1994 Jan;169(1):193-6. doi: 10.1093/infdis/169.1.193.
3
Correlation between response to acyclovir and foscarnet therapy and in vitro susceptibility result for isolates of herpes simplex virus from human immunodeficiency virus-infected patients.
Antimicrob Agents Chemother. 1994 Jun;38(6):1246-50. doi: 10.1128/AAC.38.6.1246.
4
Standardisation of a microplate in situ ELISA (MISE-test) for the susceptibility testing of herpes simplex virus to acyclovir.
J Virol Methods. 1994 Jun;48(1):93-108. doi: 10.1016/0166-0934(94)90092-2.
5
Antiviral susceptibility testing with a cell line which expresses beta-galactosidase after infection with herpes simplex virus.
Antimicrob Agents Chemother. 1995 Jun;39(6):1287-91. doi: 10.1128/AAC.39.6.1287.
6
A colorimetric assay for the measurement of the sensitivity of herpes simplex viruses to antiviral agents.
Antiviral Res. 1983 Nov;3(4):223-34. doi: 10.1016/0166-3542(83)90001-3.
7
Herpes simplex virus variants restraint to high concentrations of acyclovir exist in clinical isolates.
Antimicrob Agents Chemother. 1982 Jul;22(1):71-7. doi: 10.1128/AAC.22.1.71.
8
Plaque autoradiography assay for the detection and quantitation of thymidine kinase-deficient and thymidine kinase-altered mutants of herpes simplex virus in clinical isolates.
Antimicrob Agents Chemother. 1985 Aug;28(2):181-7. doi: 10.1128/AAC.28.2.181.
9
Improved DNA hybridization method for detection of acyclovir-resistant herpes simplex virus.
Antimicrob Agents Chemother. 1987 Oct;31(10):1465-9. doi: 10.1128/AAC.31.10.1465.
Zotero 插件